Personalised Hyperlipidaemia Therapies Guided by Pharmacogenomics

Inclusion Criteria: * Participants between 21 and 75 years old * Participants who are planning to start on statin\* medication or whose LDL-c goals have not been met, per Appendix B. * Participants who are able to communicate in English, Chinese or Malay. Participants who are planning to start or will be started on the following doses are eligible: atorvastatin 10-80 mg/day, rosuvastatin 10-40 mg/day, or simvastatin 10-40 mg/day within the last two to four weeks before enrolment Exclusion Criteria: * Participants who are statin-intolerant or in whom statins are contraindicated * Participants on a statin dosing schedule of every other day (EOD) * Participants administered on potent Cytochrome P450 3A4 (CYP3A4) or Cytochrome P450 2C9 (CYP2C9) or OATP inhibitors or inducers. * Participants on evolocumab and alirocumab prior to enrolment * Participants with documented diagnosis of psychiatric conditions * Participants requiring palliative care, end-of-life care, or those with a life expectancy of less than one year * Pregnant and lactating women * Participants with complaints of myalgia or muscle weakness at baseline, before the commencement of statin * Participants who are unable to swallow a whole statin tablet